ARUP Laboratories, Salt Lake City, a national clinical and anatomic pathology reference lab, reports that Carl R. Kjeldsberg, MD, the company’s co-founder, will retire as CEO at the end of June 2009.
He has held the position since 1993 and will continue after his retirement to serve as chairman of the board.
Edward R. Ashwood, MD, the company’s director of labs and chief medical officer, will replace Kjeldsberg as CEO on July 1, 2009. He has been with ARUP for 22 years and has been a member of its executive management team for the last 12 years. Ashwood is a tenured professor of pathology at the University of Utah School of Medicine, and is board certified in clinical and chemical pathology.
“I have a great sense of pride in what our leadership team has accomplished under my tenure as CEO and I look forward to continuing to contribute to the future success as chairman of the board,” Kjeldsberg said. “Dr Ashwood brings many years of experience and successful leadership to his new role at ARUP.”
Ashwood said, “Our priorities as a company will continue to center around our core strategic initiatives of supporting patients as well as our clients’ existing test menus by offering highly complex tests, with accompanying consultative support, to enhance their abilities to provide local and regional laboratory services.”
ARUP is an enterprise of the University of Utah and its department of pathology. With 2,100 employees, it offers more than 2,000 tests and test combinations, ranging from routine screening tests to highly esoteric molecular and genetic assays for patients nationwide. ARUP’s clients include more than half of the nation’s university teaching hospitals and children’s hospitals, and multihospital groups, major commercial labs, group purchasing organizations, military and government facilities, and major clinics. It focuses worldwide in innovative lab research and development, led by the efforts of the ARUP Institute for Clinical and Experimental Pathology®.
